UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of the earliest event reported): May 28, 2009
Valeant Pharmaceuticals International
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Delaware
|
|
1-11397
|
|
33-0628076 |
| (State or other jurisdiction of
|
|
(Commission File Number)
|
|
(I.R.S Employer |
| incorporation or organization)
|
|
|
|
Identification No.) |
One Enterprise
Aliso Viejo, California 92656
(Address of principal executive offices) (Zip Code)
(949) 461-6000
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
Item 8.01 Other Events.
Offer of Senior Unsecured Notes:
On May 28, 2009, Valeant Pharmaceuticals International (“Valeant” or the “Company”) announced that
it intends to offer, subject to market and other conditions, $300 million principal amount of
senior unsecured notes (the “Notes”). The offering is expected to commence on or about June 1,
2009. The Company intends to use the net proceeds from the offering to repurchase securities and
for general corporate purposes.
The notes will not initially be registered under the Securities Act of 1933, as amended (the
“Securities Act”) or any state securities law and may not be offered or sold in the United States
absent registration or an applicable exemption from registration under the Securities Act and
applicable state securities laws. The notes are being offered only to qualified institutional
buyers under Rule 144A and outside the United States in compliance with Regulation S under the
Securities Act.
This Current Report on Form 8-K, including the press release filed under Exhibit 99.1, does not
constitute an offer to sell any security and shall not constitute an offer, solicitation or sale in
any jurisdiction in which such offer or sale would be unlawful.
The press release dated May 28, 2009 announcing the offering of senior notes is attached as Exhibit
99.1 hereto.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| 99.1 |
|
Press release dated May 28, 2009. |